This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Sep;31(9):1163-4.

doi: 10.1016/j.leukres.2007.02.010. Epub 2007 Apr 9.

A new era for ribonucleoside reductase inhibition

Francis J Giles

PMID: 17416414
DOI: 10.1016/j.leukres.2007.02.010

Editorial

A new era for ribonucleoside reductase inhibition

Francis J Giles. Leuk Res. 2007 Sep.

. 2007 Sep;31(9):1163-4.

doi: 10.1016/j.leukres.2007.02.010. Epub 2007 Apr 9.

Author

Francis J Giles

PMID: 17416414
DOI: 10.1016/j.leukres.2007.02.010

No abstract available

PubMed Disclaimer

Comment on

Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Gojo I, Tidwell ML, Greer J, Takebe N, Seiter K, Pochron MF, Johnson B, Sznol M, Karp JE. Gojo I, et al. Leuk Res. 2007 Sep;31(9):1165-73. doi: 10.1016/j.leukres.2007.01.004. Epub 2007 Feb 26. Leuk Res. 2007. PMID: 17324462 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science